Clinical Trial News and Research

RSS

Xenon Pharmaceuticals commences phase 2 clinical trial of XEN402 therapy for PHN

Xenon Pharmaceuticals Inc. announced today that it has initiated a phase 2 clinical trial evaluating its novel topical XEN402 therapy for the treatment of PHN.

17 Aug 2010

European Cancer Cluster Meeting 2010 to be held September 15-17 in Oslo, Norway

Europe's most promising oncology biotechs and other key stakeholders will gather in Oslo, Norway, September 15-17 for the 2nd European Cancer Cluster Meeting (ECCP 2010). Co-hosted by the Oslo Cancer Cluster and the Cancer-Bio-Santé Cluster from Toulouse, the two-day meeting is a unique partnering opportunity for oncology biotech companies, business development and licensing executives from the pharmaceutical industry and investors, as well as innovative researchers and clinicians.

17 Aug 2010

Intercell reports significant increase in second quarter revenue

Today, Intercell AG announced its financial results for Q2 and H1 2010.IXIARO/JESPECT sales increased significantly from EUR 2.4m in Q2 2009 to EUR 5.2m in Q2 2010 Continued focus on growing marketing and sales of product in traveler and military markets

17 Aug 2010

Key scientific work in Cardio3 BioSciences' C-Cure stem cell heart failure treatment published in JACC

Cardio3 BioSciences, a leading Belgian biotechnology company specialising in regenerative therapies for the treatment of cardiovascular disease, today announces that the key scientific work underlying its lead pharmaceutical product C-Cure(R), a revolutionary stem cell treatment for heart failure, has been published in the Journal of the American College of Cardiology (JACC). The findings were described as "landmark work" in the accompanying editorial in today's publication.

17 Aug 2010

FDA issues Proposal to Withdraw Marketing Approval for orthostatic hypotension drug midodrine hydrochloride

The U.S. Food and Drug Administration today proposed to withdraw approval of the drug midodrine hydrochloride, used to treat the low blood pressure condition orthostatic hypotension, because required post-approval studies that verify the clinical benefit of the drug have not been done.

17 Aug 2010

Cumberland Pharmaceuticals reports 9% increase in second quarter 2010 net revenue

Cumberland Pharmaceuticals Inc. ,a specialty pharmaceutical company focused on the hospital acute care and gastroenterology markets, today announces financial results for the second quarter ending June 30, 2010, and provides revenue guidance for full year 2010.

17 Aug 2010

Emisphere second-quarter net loss increases to $13.7 million

Emisphere Technologies, Inc. today announced financial and operational results for the three and six months ended June 30, 2010.

16 Aug 2010

RhinoChill Intra-Nasal Cooling System improves survival when initiated soon after cardiac arrest

A new portable system which cools the brain via the nasal cavity may improve survival following cardiac arrest compared with standard care procedures, particularly when CPR and cooling are initiated early. Results from a recent study showed that the RhinoChill(TM) Intra-Nasal Cooling System enabled brain temperature to reach target several hours earlier than patients cooled in the emergency room. It is widely recognized that the sooner brain temperature can be reduced, the better the chances of minimizing long-term damage.

16 Aug 2010

A.P. Pharma second quarter 2010 net loss decreases to $0.09 per share

A.P. Pharma, Inc., a specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2010.“We are working expeditiously to complete the work needed to prepare for a meeting with the FDA. Once the necessary information is available, we will request an End of Review meeting to discuss the next steps for the APF530 New Drug Application.”

16 Aug 2010

KemPharm receives patent for LAT prodrug technology for Attention Deficit – Hyperactivity Disorder treatment

KemPharm, Inc. announced today that it has received a Notice of Issuance from the United States Patent and Trademark Office (USPTO) for its patent application entitled "Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same", U.S. Patent No. 7,772,222. This patent protects broad aspects of the Company's core Ligand Activated Therapy (LAT) prodrug technology platform and its application to the treatment of Attention Deficit – Hyperactivity Disorder.

16 Aug 2010

Sinovac Biotech second-quarter 2010 sales increase 131% to $10.3 million

Sinovac Biotech Ltd., a leading China-based vaccine manufacturer, announced today its unaudited financial results for the three-month and six-month periods ended June 30, 2010.

16 Aug 2010

Adeona reports $979,782 net income for second-quarter 2010 vs. $879,550 net loss for same period in 2009

Adeona Pharmaceuticals, Inc. announced its second quarter 2010 financial results and recent achievements.

16 Aug 2010

Clinical trials activity of Synexus in Hungary increases 25% in first-half of 2010

Synexus clinical trials activity in Hungary has increased by 25% during the first half of 2010. The company's Dedicated Research Centre has been operating in Hungary since 2006 and has become one of the company's most successful CEE sites. The Budapest-based operation has been involved in excess of 74 trials since being acquired by Synexus, and randomized over 600 patients.

From AES - Accelerated Enrollment Solutions 16 Aug 2010

Scientists replace human gene to preserve photoreceptor function in retinal degeneration

The easy accessibility of the eye and the established link between specific genetic defects and ocular disorders offer hope for using gene therapy to provide long-term therapeutic benefit. Two reports in the current issue of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc., describe the effective replacement of a human gene to preserve photoreceptor function in a mouse model of severe retinal degeneration. The articles are available free online.

16 Aug 2010

Inovio Pharmaceuticals 2010 second quarter net loss decreases

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2010.Total revenue was $1.1 million and $2.5 million for the three and six months ended June 30, 2010, compared to $2.5 million and $2.9 million for the three and six months ended June 30, 2009, respectively.

16 Aug 2010

BIOTRONIK DREAMS implanted in first patient as part of BIOSOLVE-I clinical study

A significant milestone has been reached in the development of a new therapy for patients suffering from coronary artery disease. On July 27, 2010 the BIOTRONIK DREAMS (Drug Eluting Absorbable Metal Scaffold) was successfully implanted in the first patient by Prof. Dr. Michael Haude at the Lukaskrankenhaus in Neuss, Germany as part of the first-in-man clinical study BIOSOLVE-I.

13 Aug 2010

Soligenix’s net loss for second-quarter 2010 decreases to $1,577,000

Soligenix, Inc., a late-stage biopharmaceutical company, announced today its financial results for the second quarter of 2010.

13 Aug 2010

Catalyst second-quarter net loss decreases to $1,328,541

Catalyst Pharmaceutical Partners, Inc. today announced its financial results for the second quarter and six months ended June 30, 2010.

13 Aug 2010

Achillion second-quarter net loss increases to $6.4 million

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three and six months ended June 30, 2010. For the second quarter of 2010, the Company reported a net loss of $6.4 million, compared with a net loss of $6.1 million for the same period last year. Cash, cash equivalents and marketable securities as of June 30, 2010 were $19.5 million.

13 Aug 2010

Hana Biosciences second-quarter net loss decreases to $6.3 million

Hana Biosciences Inc., a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the three and six months ended June 30, 2010, and provided a corporate update.

13 Aug 2010

Clinical Trial News and Research

Xenon Pharmaceuticals commences phase 2 clinical trial of XEN402 therapy for PHN

European Cancer Cluster Meeting 2010 to be held September 15-17 in Oslo, Norway

Intercell reports significant increase in second quarter revenue

Key scientific work in Cardio3 BioSciences' C-Cure stem cell heart failure treatment published in JACC

FDA issues Proposal to Withdraw Marketing Approval for orthostatic hypotension drug midodrine hydrochloride

Cumberland Pharmaceuticals reports 9% increase in second quarter 2010 net revenue

Emisphere second-quarter net loss increases to $13.7 million

RhinoChill Intra-Nasal Cooling System improves survival when initiated soon after cardiac arrest

A.P. Pharma second quarter 2010 net loss decreases to $0.09 per share

KemPharm receives patent for LAT prodrug technology for Attention Deficit – Hyperactivity Disorder treatment

Sinovac Biotech second-quarter 2010 sales increase 131% to $10.3 million

Adeona reports $979,782 net income for second-quarter 2010 vs. $879,550 net loss for same period in 2009

Clinical trials activity of Synexus in Hungary increases 25% in first-half of 2010

Scientists replace human gene to preserve photoreceptor function in retinal degeneration

Inovio Pharmaceuticals 2010 second quarter net loss decreases

BIOTRONIK DREAMS implanted in first patient as part of BIOSOLVE-I clinical study

Soligenix’s net loss for second-quarter 2010 decreases to $1,577,000

Catalyst second-quarter net loss decreases to $1,328,541

Achillion second-quarter net loss increases to $6.4 million

Hana Biosciences second-quarter net loss decreases to $6.3 million

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News